Please assess the completion status of the following clinical trial:

Trial Title: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 19 to 90 years~* On haemodialysis for the past 18 months prior to baseline~* Treatment with IV iron sucrose during the past 6 months according to the respective Summary of Product Characteristics (SmPC)~* Treatment with epoetin beta during the past 6 months according to the respective SmPC~* Regular Hb measurements and at least 5 (standard of care, approximately monthly) Hb measurements during the past 6 months~* Ferritin measurements during the past 6 months (at least 2 measurements)~* Signed informed consent~Exclusion Criteria:~* Life expectancy \<6 months~* One or more Hb measurements \<8 g/dl during the control period~* Living-donor transplant scheduled within the next 6 months~* Scheduled for switch to peritoneal dialysis or home haemodialysis~* Blood transfusion during the past 9 months~* Pregnancy or breast feeding~* Active infection~* Current malignancy or haematological disorder~* Previous severe hypersensitivity reaction to IV iron sucrose~* Serious allergic reactions to darbepoetin alfa or epoetin alfa/beta/zeta, respectively~* Current treatment with PEGylated erythropoietin~* Surgery in the past 6 months~* Surgery scheduled within the next 6 months~* Participation in a clinical trial in the past 7 months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Anemia Control Model IV iron and ESA (Type: EXPERIMENTAL): Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period

Based on this trial design, predict the completion outcome and termination type (if applicable).